The Column Group
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Headquarters Location
United States, San Francisco
About
The Column Group was established in 2006, and is a well known VC. The fund is located in United States, North America. The the headquarters of this VC is in San Francisco.
This VC was founded by Adriana Tajonar, Peter Svennilson. The overall number of key employees in the fund's team is 6.
In 2015, the fund's activity was at its peak. Additionally, in 2019 the fund was active. Deals in the range of 10 - 50 millions dollars are most common for this fund. The fund typically enters into 2-6 deals annually. The most exits for the fund occurred in 2019. In comparison with other funds, The Column Group makes 10 percentage points less than the average number of lead investments. In terms of the fund's performance, this VC has 14 percentage points more exits when compared to other organizations.
The usual method for the fund is to invest in rounds with 5-6 other investors. Aside from The Column Group, start-ups are often funded by Topspin Partners, OrbiMed, OUP (Osage University Partners) and 30 other funds. The most common co-investors for the fund are OUP (Osage University Partners), Celgene, Versant Ventures and also 49 different VCs. In subsequent rounds, the fund is usually supported by Kleiner Perkins, Foresite Capital, Venrock, out of 47 investors from our database.
Among their most successful investment fields, we have identified Health Care, Medical Device. Also, because of its portfolio diversification tendency, we can highlight 9 more industries for this fund. The fund has no a preferred number of founders for start-ups that it invests in. If there are 4 founders in the start-up, the probability of getting the investment is low. Flexus Biosciences, NGM Biopharmaceuticals, Surrozen are amongst the various portfolio companies of this fund. The country of its establishment and the country of its most frequent investments coincides - United States. Also, a start-up has to be aged 2-3 years to expect investment from this fund.
Year Founded
2006
Fund Activity
Operative
Mail Rule [rules by which you can get an email of an interesting for you fund employee, knowing only the name and surname of this employee]
Domain name: thecolumngroup.net; User name format in descending order of probability: first
Group Appearance [how often fund is operating separately from groups with shared interest]
100.0% of cases
Investments per Year [average amount of rounds in which fund participates each year]
4-6
Follow-on Index [how often fund is ready to support its portfolio startup at next rounds]
43.1% of cases
Average Multiplicator [the average ratio of the last valuation of portfolio startups to their total amount of financing raised]
x7.1
Average Portfolio Company
Exit Age [the average age of portfolio startups at which they go public or become acquired]
4.6 years
Success / Strategy Similarity
Index [the matching between fund's investment strategy and its proved successes in the form of portfolio startups high valuations]
0.19 out of 1
Number of Unicorns [amount of portfolio companies, which were valuated at more then $1B]
3
Funds Investing in Previous
Rounds
Funds Investing Together
Funds Investing in Following
Rounds
If you have found a spelling error or the data isn't actual, please, notify us by selecting that text and pressing Ctrl+Enter.
Unicorn Nest finds the most relevant investors for startups.
Tell us about your startup and get the list of VCs most likely to invest in your next round.
Find your perfect investor now
- No reviews are submitted yet.
By posting comments on our website you confirm and acknowledge that:
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Complain
To post a comment or write a complain, please sign in with LinkedIn
